NCT06384443Completed
Proton Pump Inhibitors in Cirrhotic Patients
Inappropriate Use of Proton Pump Inhibitors in Patients With Liver Cirrhosis
Source: ClinicalTrials.gov · Last updated 25 Apr 2024
Brief summary (registry, in English)
Proton pump inhibitors (PPIs) inappropriate use, in patients with cirrhosis, presents a significant clinical challenge. This study evaluates overprescription and misuse of PPIs in cirrhotic patients. The patterns of use of PPIs will be classified into two groups based on adherence to the proven indications: Group A: Inappropriate use of PPI, Group B: Appropriate use of PPI. We will estimate the prevalence of PPI misuse in cirrhotics and correlate it with different factors.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1000 (actual)
- First submitted
- 22 Apr 2024
- Start date
- 1 Oct 2020
- Primary completion date
- 1 Mar 2024
- Lead sponsor
- National Liver Institute, Egypt
- Diseases
- High blood pressure
- NCT number
- NCT06384443
What you commit to
- Study type: Observational
- Participants enrolled: 1000
- From 1 Oct 2020 to the primary completion date, 1 Mar 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Refusal to sign the informed consent form or failure to provide the required information
Who the study is looking for
- Patients receiving proton pump inhibitors at the time of enrollment.
Age in the registry: 18 years to 70 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Liver Institute, Menoufia University Coordinator of this site? Confirm its status | Shibīn al Kawm | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.